Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,280 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07196644RecruitingPhase 2
A study of a new drug for certain cancers with a specific gene change
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
Beverly Hills, CaliforniaAges 12 years+ - NCT07201558RecruitingPhase 1
Surovatamig safety study for rheumatoid arthritis or lupus
This trial tests surovatamig, a new experimental treatment, to see if it's safe and how the body processes it in adults with moderate-to-severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). It may be an option if you've tried other biologic or targeted therapies without success.
Birmingham, AlabamaAges 18–65 - NCT07195890Enrolling by invitation
Teen Mental Health First Aid for Hong Kong students
This trial tests whether a Teen Mental Health First Aid course helps students in Hong Kong secondary schools better support peers with mental health struggles. It is for students in Forms 4–6 whose schools are already offering the course.
Hong Kong, HksarAges 14–18 - NCT05792852Recruiting
Help for disabled people facing social participation challenges
This study aims to improve how supported people with disabilities from underrepresented groups can take part in social activities after COVID. You may be invited if you have trouble with social participation and can communicate your interest.
Chicago, IllinoisAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07185919Recruiting
Odevixibat (Bylvay) study for PFIC patients in South Korea
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
GyeongsangAges Any age - NCT07184944RecruitingPhase 3
Study of Duvakitug for moderate to severe Crohn's disease
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
Colorado Springs, ColoradoAges 16–80 - NCT07190222RecruitingPhase 3
New medicine for COPD with frequent flare-ups
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Birmingham, AlabamaAges 40–80 - NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Birmingham, AlabamaAges 18 years+ - NCT07190248RecruitingPhase 3
Calderasib plus other treatments for advanced non-small cell lung cancer
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
Birmingham, AlabamaAges 18 years+ - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Peoria, ArizonaAges 16–80 - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07190209RecruitingPhase 3
Testing lunsekimig for COPD with frequent flare-ups
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
Chandler, ArizonaAges 40–80 - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Fullerton, CaliforniaAges 18 years+ - NCT07187401RecruitingPhase 1/Phase 2
Study of a new RNA drug for PNH anemia
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
Toronto, OntarioAges 18 years+ - NCT07189949RecruitingPhase 1
Study of HRS-2329 for advanced solid tumors with RAS changes
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Tucson, ArizonaAges 16–80 - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT06944171Recruiting
How brain-related challenges affect daily life in children with cerebral palsy
This study looks at how impairments like muscle stiffness or weakness affect daily activities and participation in children (ages 6–12) with cerebral palsy. It could help families better understand their child's needs.
AnkaraAges 6–12 - NCT06882408Recruiting
Vision screening study for children
This study tests a special camera that checks for vision problems in children. It is designed to find nearsightedness, farsightedness, and other eye issues. Kids will have a quick vision check during one visit.
Nancy, FranceAges 3–8 - NCT07180563RecruitingPhase 1/Phase 2
Berberine and doxycycline for chronic endometritis
This trial tests if adding berberine (a plant compound) to the antibiotic doxycycline works better than doxycycline alone for treating chronic endometritis, a long-term inflammation of the womb lining that can affect fertility. It may help women who have this condition.
Yiwu, ZhejiangAges 20 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,280 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.